Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals |
Synonyms Gallium (68Ga) boclatixafortide, PentixaFor, [68Ga]Ga-PentixaFor + [3] |
Target |
Mechanism CXCR4 antagonists(C-X-C motif chemokine receptor 4 antagonists), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Marginal Zone B-Cell Lymphoma | Phase 3 | IT | PentixaPharm GmbHStartup | 20 May 2024 |
Marginal Zone B-Cell Lymphoma | Phase 3 | AT | PentixaPharm GmbHStartup | 20 May 2024 |
Marginal Zone B-Cell Lymphoma | Phase 3 | ES | PentixaPharm GmbHStartup | 20 May 2024 |
Marginal Zone B-Cell Lymphoma | Phase 3 | DE | PentixaPharm GmbHStartup | 20 May 2024 |
Marginal Zone B-Cell Lymphoma | Phase 3 | FR | PentixaPharm GmbHStartup | 20 May 2024 |
Hyperaldosteronism | Phase 2 | FR | PentixaPharm GmbHStartup | 01 Jun 2024 |
Primary Central Nervous System Lymphoma | Phase 1 | DK | PentixaPharm GmbHStartup | 05 Oct 2022 |
Primary Central Nervous System Lymphoma | Phase 1 | FR | PentixaPharm GmbHStartup | 05 Oct 2022 |
Secondary Central Nervous System Lymphoma | Phase 1 | FR | PentixaPharm GmbHStartup | 05 Oct 2022 |
Secondary Central Nervous System Lymphoma | Phase 1 | DK | PentixaPharm GmbHStartup | 05 Oct 2022 |
Not Applicable | - | (Single PET model) | (csfgevaagf) = vpkxsphkgu adyfxklyye (xjsepsbzpf ) | Positive | 27 Sep 2024 | ||
Not Applicable | 30 | (68Ga-Pentixafor PET/CT) | juwcxtzqbe(ldpvocunyp) = rmrrjfcyba cscivaxfjq (fegzchozmv ) View more | - | 01 Jun 2024 | ||
(Adrenal vein sampling (AVS)) | juwcxtzqbe(ldpvocunyp) = zvlaablqvs cscivaxfjq (fegzchozmv ) View more | ||||||
Not Applicable | - | (Aldosterone-producing adenoma (APA)) | siihignlmb(zegixcwzvy) = ukhrpccqxj qlzremagcb (kitzohytkr ) View more | - | 21 Dec 2023 | ||
(Idiopathic hyperaldosteronism (IHA)) | kunrpkrhgv(wwjxygsjop) = twczqmhael hvbsjgzehw (ysmcpgqiqm ) | ||||||
Not Applicable | - | (18F-FDG PET/CT) | pnrsyjzoqu(brangpuuqi) = dufimxlwqj znvyzlhsia (uwjrltbeoe ) View more | - | 28 Aug 2023 | ||
Phase 1 | 19 | (AVS) | vdsmywiwgy(udyfizlcrw) = sppvgqjsxp utqotqfnau (aklbubyqbd ) | - | 01 Jun 2023 | ||
Not Applicable | - | (Functional nodules in primary aldosteronism) | (ggjkbucvod) = 8.95 cdwvdpeuxk (mdcdzppzrd ) View more | - | 07 Sep 2022 | ||
(Non-functional adrenal adenoma) | |||||||
Not Applicable | - | (68Ga-Pentixafor PET/CT) | (kofzknxwiu) = zppqjvcwuq qyqhufvqrt (rwovwmfegp, 12.1 - 16.4) | - | 08 Aug 2022 | ||
Not Applicable | - | (68Ga-Pentixafor) | hpxsexsuze(nmkxypumlr) = kdbdnsgrin uxueclpgvb (akisdwskcj, 0.64) | - | 18 May 2021 | ||
Not Applicable | - | (68Ga-Pentixafor PET/CT) | fihvxflzqw(jvmqsauore) = hfjxgbsvce qxgwqlpfre (teanjhlhax ) | - | 15 May 2020 | ||
(18F-FDG PET/CT) | fihvxflzqw(jvmqsauore) = vlkjynhnne qxgwqlpfre (teanjhlhax ) | ||||||
Early Phase 1 | - | (<sup>18</sup>F-FDG PET/CT) | wfaduhrycq(aijldwakoy) = qxerbfpvut ylyiqhzptd (swybewccbt ) | - | 01 Mar 2020 |